Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Acquires Additional Securities of Resverlogix Corp.
- Written by Newsfile
Calgary, Alberta--(Newsfile Corp. - May 21, 2021) - Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink") announces that on May 13, 2021, it acquired 10% secured convertible debentures due May 13, 2022, of Resverlogix Corp. (TSX: RVX) (OTC Pink: RVXCF) (the "Company") in the principal amount of US$6 million and 300,000 common share...